{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:48:26Z","timestamp":1792900106416,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jidinnovations.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JID Innovations"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.xjidi.2025.100410","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T23:52:58Z","timestamp":1756857178000},"page":"100410","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Assessing Treatment Efficacy for Dermatologic Immune-Related Adverse Events: A Systematic Review"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3988-9519","authenticated-orcid":false,"given":"Christian L.","family":"Bailey-Burke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0317-4156","authenticated-orcid":false,"given":"Kristin A.","family":"Tissera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6748-0229","authenticated-orcid":false,"given":"Lauren","family":"Baughman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3870-4226","authenticated-orcid":false,"given":"Samantha A.","family":"Polly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0460-6400","authenticated-orcid":false,"given":"Meenal","family":"Kheterpal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xjidi.2025.100410_bib1","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1634\/theoncologist.2019-0796","article-title":"Hypertrophic Lichen Planus with histological features of squamous cell carcinoma associated with immune checkpoint blockade therapy","volume":"25","author":"Ameri","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.xjidi.2025.100410_bib2","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.annonc.2021.02.016","article-title":"IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies","volume":"32","author":"Barrios","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.xjidi.2025.100410_bib3","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1111\/jdv.14011","article-title":"Anti-PD1-induced psoriasis: a study of 21 patients","volume":"31","author":"Bonigen","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.xjidi.2025.100410_bib4","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1177\/1078155219890659","article-title":"Toxic epidermal necrolysis associated with pembrolizumab","volume":"26","author":"Cai","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.xjidi.2025.100410_bib5","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007675","article-title":"Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy","volume":"12","author":"Chen","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.xjidi.2025.100410_bib6","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/cup.13013","article-title":"PD-1 inhibitor-associated lichenoid inflammation with incidental suprabasilar acantholysis or vesiculation-Report of 4 cases","volume":"44","author":"Chou","year":"2017","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.xjidi.2025.100410_bib7","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jaad.2018.10.062","article-title":"Inflammatory eruptions associated with immune checkpoint inhibitor therapy: a single-institution retrospective analysis with stratification of reactions by toxicity and implications for management","volume":"80","author":"Coleman","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2025.100410_bib8","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/cup.13587","article-title":"Pembrolizumab-induced pseudoepitheliomatous eruption consistent with hypertrophic lichen planus","volume":"47","author":"Coscarart","year":"2020","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.xjidi.2025.100410_bib9","first-page":"SF389716s3","article-title":"INDIVIDUAL ARTICLE: USCOM algorithm for the prevention and management of cutaneous immunotherapy-related adverse events","volume":"22","author":"Deutsch","year":"2023","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.xjidi.2025.100410_bib10","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1684\/ejd.2017.3023","article-title":"Cutaneous adverse effects during ipilimumab treatment for metastatic melanoma: a prospective study","volume":"27","author":"Dika","year":"2017","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.xjidi.2025.100410_bib11","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/CMR.0000000000000437","article-title":"Sarcoid-like reactions in patients receiving modern melanoma treatment","volume":"28","author":"Dimitriou","year":"2018","journal-title":"Melanoma Res"},{"key":"10.1016\/j.xjidi.2025.100410_bib12","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1634\/theoncologist.2018-0531","article-title":"Resolution of pembrolizumab-associated steroid-refractory lichenoid dermatitis with cyclosporine","volume":"24","author":"Fixsen","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.xjidi.2025.100410_bib13","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1158\/1078-0432.CCR-15-2872","article-title":"Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy","volume":"22","author":"Goldinger","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.xjidi.2025.100410_bib14","doi-asserted-by":"crossref","first-page":"728","DOI":"10.3390\/jcm10040728","article-title":"The clinical and histopathological features of cutaneous immune-related adverse events and their outcomes","volume":"10","author":"Hashimoto","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.xjidi.2025.100410_bib15","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jaad.2021.11.050","article-title":"Histologic subtype of cutaneous immune-related adverse events predicts overall survival in patients receiving immune checkpoint inhibitors","volume":"87","author":"Hirotsu","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2025.100410_bib16","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.xjidi.2025.100410_bib17","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/CMR.0000000000000260","article-title":"Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies","volume":"26","author":"Hwang","year":"2016","journal-title":"Melanoma Res"},{"key":"10.1016\/j.xjidi.2025.100410_bib18","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.jaad.2022.09.012","article-title":"Dermatology evaluation for cutaneous immune-related adverse events is associated with improved survival in cancer patients treated with checkpoint inhibition","volume":"88","author":"Jacoby","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2025.100410_bib20","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1097\/PAS.0000000000000900","article-title":"Cutaneous eruptions in patients receiving immune checkpoint blockade: clinicopathologic analysis of the nonlichenoid histologic pattern","volume":"41","author":"Kaunitz","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.xjidi.2025.100410_bib21","first-page":"1","article-title":"Immune-related lichenoid mucocutaneous erosions during anti-PD-1 immunotherapy in metastatic renal cell carcinoma - a case report","volume":"23","author":"Lindner","year":"2018","journal-title":"Urol Case Rep"},{"key":"10.1016\/j.xjidi.2025.100410_bib22","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/9602540","article-title":"Immune toxicity with checkpoint inhibition for metastatic melanoma: case series and clinical management","volume":"2018","author":"Lomax","year":"2018","journal-title":"J Skin Cancer"},{"key":"10.1016\/j.xjidi.2025.100410_bib23","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/ijd.13984","article-title":"A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors","volume":"57","author":"Lopez","year":"2018","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.xjidi.2025.100410_bib24","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1111\/jdv.19112","article-title":"Cutaneous manifestations induced by check point inhibitors in 120 melanoma patients-The European MelSkinTox study","volume":"37","author":"L'Orphelin","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.xjidi.2025.100410_bib25","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/cup.13739","article-title":"Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: a diagnostic pitfall for superficially invasive squamous cell carcinoma","volume":"47","author":"Marques-Piubelli","year":"2020","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.xjidi.2025.100410_bib26","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jdcr.2021.03.015","article-title":"Apremilast for immune checkpoint inhibitor-induced psoriasis: a case series","volume":"11","author":"Mayor Ibarguren","year":"2021","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.xjidi.2025.100410_bib27","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jaad.2018.05.035","article-title":"Characterization of dermatitis after PD-1\/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: a retrospective case-control study","volume":"79","author":"Min Lee","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2025.100410_bib28","article-title":"A novel approach to the treatment of pembrolizumab-induced psoriasis exacerbation: a case report","volume":"11","author":"Monsour","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.xjidi.2025.100410_bib29","article-title":"A case of de novo psoriasis secondary to nivolumab in a patient with metastatic renal cell carcinoma","volume":"13","author":"Mullangi","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.xjidi.2025.100410_bib30","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jamaoncol.2021.4318","article-title":"Management of cutaneous immune-related adverse events in patients with cancer treated with immune checkpoint inhibitors: a systematic review","volume":"8","author":"Nadelmann","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.xjidi.2025.100410_bib31","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40425-018-0475-y","article-title":"Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF\/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series","volume":"7","author":"Naqash","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.xjidi.2025.100410_bib33","author":"Phillips"},{"key":"10.1016\/j.xjidi.2025.100410_bib34","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1200\/JCO.18.02141","article-title":"Treatment outcomes of immune-related cutaneous adverse events","volume":"37","author":"Phillips","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.xjidi.2025.100410_bib35","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jaad.2020.09.054","article-title":"Cutaneous adverse events caused by immune checkpoint inhibitors","volume":"85","author":"Quach","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2025.100410_bib36","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/CJI.0000000000000181","article-title":"Sarcoidosis following anti-PD-1 and anti-CTLA-4 therapy for metastatic melanoma","volume":"40","author":"Reddy","year":"2017","journal-title":"J Immunother"},{"key":"10.1016\/j.xjidi.2025.100410_bib37","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1111\/ijd.15163","article-title":"Dermatological side effects rarely interfere with the continuation of checkpoint inhibitor immunotherapy for cancer","volume":"59","author":"Rovers","year":"2020","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.xjidi.2025.100410_bib38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/1346-8138.17039","article-title":"Immune checkpoint inhibitor-induced epidermal necrolysis: a narrative review evaluating demographics, clinical features, and culprit medications","volume":"51","author":"Satoh","year":"2024","journal-title":"J Dermatol"},{"key":"10.1016\/j.xjidi.2025.100410_bib39","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ejca.2017.03.026","article-title":"Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma patients","volume":"81","author":"Saw","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.xjidi.2025.100410_bib40","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1200\/JOP.19.00751","article-title":"Pembrolizumab-induced bullous pemphigoid treated with rituximab","volume":"16","author":"Sharma","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.xjidi.2025.100410_bib41","doi-asserted-by":"crossref","DOI":"10.1177\/1758834017751634","article-title":"Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management","volume":"10","author":"Shen","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.xjidi.2025.100410_bib42","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/jamadermatol.2016.2226","article-title":"Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy","volume":"152","author":"Shi","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.xjidi.2025.100410_bib43","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jaad.2018.07.008","article-title":"Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy","volume":"79","author":"Siegel","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2025.100410_bib44","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jamadermatol.2017.0091","article-title":"Rituximab treatment of nivolumab-induced bullous pemphigoid","volume":"153","author":"Sowerby","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.xjidi.2025.100410_bib45","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15472","article-title":"Multiple eruptive squamoproliferative lesions during anti-PD1 immunotherapy for metastatic melanoma: pathogenesis, immunohistochemical analysis and treatment","volume":"35","author":"Star","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.xjidi.2025.100410_bib46","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1001\/jamadermatol.2015.5210","article-title":"Inverse psoriasiform eruption during pembrolizumab therapy for metastatic melanoma","volume":"152","author":"Totonchy","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.xjidi.2025.100410_bib47","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/ajd.13660","article-title":"Severe progressive scarring pembrolizumab-induced lichen planopilaris in a patient with metastatic melanoma","volume":"62","author":"Uthayakumar","year":"2021","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.xjidi.2025.100410_bib48","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.2217\/imt-2022-0113","article-title":"Cutaneous metastases at the sites of pembrolizumab-induced bullous pemphigoid lesions in a patient with melanoma","volume":"14","author":"V\u00e1nyai","year":"2022","journal-title":"Immunotherapy"},{"key":"10.1016\/j.xjidi.2025.100410_bib49","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jdcr.2020.01.008","article-title":"Bullous pemphigoid associated with cemiplimab therapy in a patient with locally advanced cutaneous squamous cell carcinoma","volume":"6","author":"Virgen","year":"2020","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.xjidi.2025.100410_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053745","article-title":"The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network","volume":"8","author":"Voskens","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.xjidi.2025.100410_bib51","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.currproblcancer.2017.10.003","article-title":"Anti-PD1\/PDL1 induced psoriasis","volume":"41","author":"Voudouri","year":"2017","journal-title":"Curr Probl Cancer"},{"key":"10.1016\/j.xjidi.2025.100410_bib52","doi-asserted-by":"crossref","first-page":"6110","DOI":"10.12998\/wjcc.v10.i18.6110","article-title":"Pembrolizumab-induced Stevens-Johnson syndrome in advanced squamous cell carcinoma of the lung: a case report and review of literature","volume":"10","author":"Wu","year":"2022","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.xjidi.2025.100410_bib53","article-title":"Toxic epidermal necrolysis-like reaction following combination therapy with Camrelizumab and Apatinib for advanced gallbladder carcinoma","volume":"11","author":"Yang","year":"2021","journal-title":"Front Oncol"}],"container-title":["JID Innovations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026725000669?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026725000669?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T14:06:34Z","timestamp":1769522794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667026725000669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2667026725000669"],"URL":"https:\/\/doi.org\/10.1016\/j.xjidi.2025.100410","relation":{},"ISSN":["2667-0267"],"issn-type":[{"value":"2667-0267","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing Treatment Efficacy for Dermatologic Immune-Related Adverse Events: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"JID Innovations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xjidi.2025.100410","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}],"article-number":"100410"}}